When it comes to treating advanced cancers, having access to the latest therapies can make a significant difference for patients. American Oncology Network (AON) (OTCQX: AONC), one of the fastest-growing community oncology groups in the United States, is making sure that more patients across the country have just that opportunity. Recently, AON announced an expansion of radioligand therapy (RLT) offerings at six of its partner practices, ensuring that people with certain metastatic and rare cancers can receive targeted, innovative treatments close to home.
As of May 21, 2025, more than 300 radioligand therapy treatments have already been delivered to nearly 70 patients at five AON affiliate practices. The demand for these therapies is clear, and AON is responding by rolling out access to even more sites. The six practices now offering these advanced therapies include Summit Cancer Centers, Cancer & Blood Specialists of Arizona, Woodlands Cancer Institute, Messino Cancer Centers, Zangmeister Cancer Center, and Genesis Cancer and Blood Institute.
Radioligand therapy is a specialized approach that uses radioactive molecules to target and destroy cancer cells with precision. Unlike traditional radiation, which can affect healthy tissue, radioligand therapy delivers radiation directly to the tumor, minimizing side effects and improving patient outcomes. “Radioligand therapy allows us to deliver highly targeted radiation directly to cancer cells, minimizing damage to healthy tissue and improving patient outcomes,” explains Guy Messer, AON’s vice president of radiation and radiology services.
American Oncology Network (AON) practices now provide access to three FDA-approved radiopharmaceutical therapies, each targeting specific advanced cancer types. Pluvicto™ is used for metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen (PSMA), marking it as the first FDA-approved targeted radioligand therapy for this group of patients. Lutathera® is intended for adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare but increasingly recognized cancer affecting the digestive system, and remains the only FDA-approved radiopharmaceutical for this indication in adults. Xofigo® (radium-223 dichloride) is specifically approved for men with mCRPC that has spread to the bone and who have already undergone androgen deprivation therapy, offering a targeted option for patients with bone metastases.
These therapies work by attaching a radioactive isotope to a molecule that targets cancer cells, delivering precise radiation to tumors while minimizing damage to healthy tissue. By expanding the availability of these advanced radiopharmaceuticals in community oncology settings, AON is helping more patients access cutting-edge, personalized cancer care closer to home
Dr. Stephen “Fred” Divers, AON’s chief medical officer, emphasizes the importance of making these therapies available in community settings. “Continuing to increase the availability of these advanced radiopharmaceutical therapies in community oncology practices across the nation is a major step forward in personalized cancer care,” he says. “It’s part of AON’s broader mission to ensure patients nationwide have access to the latest innovations in oncology, without sacrificing the personalized care they receive close to home.”
AON’s approach is rooted in its physician-led model, which aims to keep practices independent while providing the resources and support needed to deliver high-quality, innovative care. Founded in 2018, AON now counts more than 290 providers across 21 states, making it a significant force in community oncology. The network is committed to health equity, ensuring that all patients, regardless of location or background, have access to cutting-edge cancer care.
AON expects to see continued growth in the use of radioligand therapies as more practices develop the necessary infrastructure and regulatory approvals. This expansion is a testament to the network’s dedication to innovation and patient-centered care.
